FOLH1 and neoplasm: Radiolabeled drugs appeared as a promising therapeutic option, targeting either the microenvironment of sclerotic bone metastases (e.g., samarium-153 lexidronam [5], strontium-89 dichloride [6] or radium-223 dichloride [7]) or, more recently, directly tumor cells (e.g., PSMA ligands labelled with lutetium-177).